Novo Holdings A/S

Profile

Novo Holdings A/S is a Danish investment company based in Hellerup, responsible for managing the assets and wealth of the Novo Nordisk Foundation. Founded in 1999, Novo Holdings is the main shareholder of Novo Nordisk and Novozymes, operating with a team that spans across Copenhagen, London, San Francisco, Boston, Singapore, Shanghai, and Mumbai. Its focus lies in delivering strong returns while promoting health and sustainability, making it distinct with its long-term perspective and value-driven investment approach. The firm employs a diverse team that is committed to high performance with respect and responsibility.

Novo Holdings invests primarily in life sciences, covering sectors including healthcare services, pharmaceuticals, biotechnology, and medical devices. They manage a broad portfolio of equities, bonds, and private equity investments with assets under management totalling DKK 694 billion (approximately EUR 93 billion as of 2025). The firm's geographic focus includes North America, Europe, and Asia, allowing them to support a global array of companies.

Some notable investments by Novo Holdings include Myricx Bio, which was acquired by Novartis, Hemab Therapeutics, which completed a successful Nasdaq IPO, and LimmaTech Biologics, which was acquired by Lilly. These investments reflect their strategy in the healthcare sector, emphasizing a commitment to companies that align with their values of health and sustainability.